Premium
Developing long‐acting growth hormone formulations
Author(s) -
Cawley Pippa,
Wilkinson Ian,
Ross Richard J.
Publication year - 2013
Publication title -
clinical endocrinology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.055
H-Index - 147
eISSN - 1365-2265
pISSN - 0300-0664
DOI - 10.1111/cen.12240
Subject(s) - growth hormone , endocrinology , human growth hormone , medicine , hormone , recombinant dna , biology , biochemistry , gene
Summary Daily recombinant growth hormone ( GH ) restores normal growth and body composition in GH ‐deficient children and adults; however, daily injections are inconvenient and can be distressing for some children. On top of this compliance is a problem in up to 75% of children. Developing long‐acting GH formulations has proved challenging, and questions remain regarding safety and efficacy. In this review, we focus on the rationale for generating long‐acting GH agonists and the technologies being developed to deliver prolonged exposure to GH .